The use of clozapine among individuals with intellectual disability: a review.

The authors hunted every paper on clozapine for challenging behavior in people with intellectual disability. They read controlled trials, case reports, and chart reviews published up to 2009.

After screening, only a handful of small studies remained. Most had no control group and weak outcome measures.

The evidence was too thin to say clozapine helps or harms this group. No study showed clear, lasting drops in aggression or self-injury.

Side-effect data were also missing. The review calls the practice experimental.

Desarkar et al. (2018) seems to disagree. Their single adult with moderate ID plus catatonia got better after clozapine plus ECT. The difference is scope: N et al. looked at everyday challenging behavior, while Pushpal targeted hard-core psychosis and catatonia.

Patton et al. (2020) backs the caution. They saw adults in crisis loaded with psychotropics and still melting down. Heavy drug mixes often caused the very agitation teams wanted to stop.

Klein et al. (2024) adds fresh numbers: nearly one in three youth with IDD already receives two or more psychotropic classes yearly. The 2010 warning against low-evidence drugs like clozapine still rings true.

Before you sign off on clozapine for aggression, demand a functional assessment and two solid medication trials. Document baseline seizures, drooling, and sedation. If the psychiatrist still wants clozapine, insist on weekly blood draws and a clear exit plan. Your data may become the evidence this population still lacks.